Senior Vice President, Strategic Planning

Dr. Tyree is responsible for the operational management of company programs and evaluation of candidates from HUYABIO’s database of China-sourced therapeutic opportunities. Dr. Tyree has over 22 years drug discovery experience in oncology, cardiology, inflammatory disease, and neurology. At Ligand Pharmaceuticals and TorreyPines Therapeutics, he worked on projects with Abbott, GlaxoSmithKline, Bristol-Myers Squibb, and Eisai. He contributed to the discovery of Promacta, the first oral thrombopoietin receptor agonist, and the first published gamma secretase modulator for Alzheimer’s. He received a BSc from McGill University, a PhD in Biology from the University of California, San Diego, and performed postdoctoral cancer research at the McArdle Laboratory. Dr. Tyree is an Advisor to China’s Hangzhou High Tech Incubator, an Adjunct Clinical Assistant Professor of Pharmacy Practice and Advisory Board member at the Keck Graduate Institute School of Pharmacy.

Curtis Tyree